Danusertib (PHA-739358)

Catalog No.S1107

Danusertib (PHA-739358) Chemical Structure

Molecular Weight(MW): 474.55

Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.

Size Price Stock Quantity  
In DMSO USD 238 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Mice bearing subcutaneous allografts of conditional patched mutant tumor cells were treated twice weekly with vehicle (saline) or 30 mg/kg PHA-739358. (B)Images of tumors. (C) Tumor weights. Each point represents a single tumor, and grey lines represent mean tumor weights, which were significantly different between vehicle and PHA-739358 treated mice (p < 0.05, based on paired two-tailed t-test).

    Cancer Res 2013 73(20), 6310-22. Danusertib (PHA-739358) purchased from Selleck.

    For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of PHA-739358 by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Danusertib (PHA-739358) purchased from Selleck.

  • AsPC-1 cells were treated with PHA-739358 (PHA) (3 uM), imatinib (15 uM), or combination of PHA and imatinib for 72 hours and Bcl2 and Bcl-xL expression levels by Western blotting.

    Biochem Pharmacol 2012 83(4), 452-61. Danusertib (PHA-739358) purchased from Selleck.

    Western blot analysis of Histone and Aurora kinase. 0-10μM PHA739358 was added.

    Dr. Zhang of Tianjin Medical University. Danusertib (PHA-739358) purchased from Selleck.

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Danusertib (PHA-739358) is an Aurora kinase inhibitor for Aurora A/B/C with IC50 of 13 nM/79 nM/61 nM in cell-free assays, modestly potent to Abl, TrkA, c-RET and FGFR1, and less potent to Lck, VEGFR2/3, c-Kit, CDK2, etc. Phase 2.
Aurora A [1]
(Cell-free assay)
Abl [1]
(Cell-free assay)
RET [1]
(Cell-free assay)
TrkA [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
13 nM 25 nM 31 nM 31 nM 47 nM
In vitro

Danusertib inhibits the activities of other kinases such as FGFR1, Abl, Ret and Trka, with IC50 of 47 nM, 25 nM, 31 nM and 31 nM, respectively. In a cell assay, after treatment of wild-type and p53-deficient MEFs with Danusertib, the wild-type cells undergo an arrest in mitosis (4N) that is maintained for up to 48 h. The p53-deficient cells on the other hand do not arrest at the 4N DNA stage, but continues with additional rounds of DNA synthesis to become >8N. Treatment with Danusertib results in an increase in p53 protein levels and an associated increase in p21 protein, which is known to be transcriptionally regulated by p53. [1] Increasing concentrations of Danusertib produces a dose-dependent reduction of cell growth after 48 hours in BCR-ABL-positive (K562, BV173) and BCR-ABL-negative (HL60) cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A2780 cells MnPYVJJwdGmoZYLheIlwdiCjc4PhfS=> MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IFGyO|gxKGOnbHzzMEBKSzVyPUK4JI5O NFvrSVAyPzF{NUK3PS=>
HCT116 cells NVvJeYg6WHKxbHnm[ZJifGmxbjDhd5NigQ>? NFTMUHpCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhEXDFzNjDj[YxteyxiSVO1NF0{OSCwTR?= NXzFdpVwOTdzMkWyO|k>
human HCT116 cells MmD5VJJwdGmoZYLheIlwdiCjc4PhfS=> MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDhd5Nme3OnZDDhd{BDemSXIHnuZ49zeG:{YYTpc44h[W[2ZYKgO|IhcHK|LDDJR|UxRTNzIH7N MXexPVMzODR6OR?=
HCT116 cells M3:ySWZ2dmO2aX;uJIF{e2G7 NXPMeYJ[S2WubDDjfYNt\SCjcoLld5QhcW5iSFPUNVE3KGOnbHzzJIJ6KGGlY4XteYxifGmxbjDheEBIOi:PIIDoZZNmNCCHQ{WwQVgxKG6P NXj1ZVdvOTdzMkWyO|k>
MCF7 cells MUfQdo9tcW[ncnH0bY9vKGG|c3H5 NGT5VnhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JG1ETjdiY3XscJMtKEmFNUC9PFAhdk1? MVqxO|EzPTJ5OR?=
HeLa cells NYHEWJV3WHKxbHnm[ZJifGmxbjDhd5NigQ>? NGOxfpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGhmVGFiY3XscJMtKEmFNUC9NE4yPCEQvF2= M3m3flE4OTJ3Mke5
human MOLT4 cells NVSxOnROS3m2b4TvfIlkyqCjc4PhfS=> MXfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxiZ4Lve5RpKGGodHXyJFQh\GG7czDifUBE\WyuIGTpeIVzKEKudXWg[Y5lNXCxaX70JIF{e2G7LDDFR|UxRTBwMUWg{txO MnH5NlI5QDl3NkG=
human HepG2 cells M2PyPGN6fG:2b4jpZ:Kh[XO|YYm= NWHHbGhtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUGWyR{KgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiVFO1NF01KM7:TR?= NWr5OnFYOjR7MUC3OlY>
human A2780 cells NYfaToFXWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFXhOI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO|gxKGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kA1ViCGTlGsJGlEPTB;Mkig{txO M{K5WFE6OzJyNEi5
HCT116 cells M{HOeWZ2dmO2aX;uJIF{e2G7 NUTIUIJMUW6qaXLpeIlwdiCxZjDobZN1d26nIHizJJBpd3OyaH;yfYxifGmxbjDpckBJS1RzMU[gZ4VtdHNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ M33QPFE4OTJ3Mke5

... Click to View More Cell Line Experimental Data

In vivo Administration of 25 mg/kg Danusertib (b.d. i.v.) to HL-60 xenograft rats results in 75% inhibition of tumor growth with complete regression in one animal. Danusertib results in biomarker modulation accompanied by inhibition of tumor growth. This is compatible with an expected mechanism of action of aurora kinase inhibition. [1] Danusertib significantly inhibits proliferation of K562 cells and virtually suppressed tumor growth during the 10-day treatment period. [3]


Kinase Assay:[1]
+ Expand

Biochemical kinase Assays:

The Km values for ATP and the specific substrate are initially determined, and each assay is then run at optimized ATP (2Km) and substrate (5Km) concentrations. This setting enabled direct comparison of IC50 values of Danusertib across the applied kinase selectivity screening panel for the evaluation of the selectivity profile.
Cell Research:[3]
+ Expand
  • Cell lines: CD34+ cells
  • Concentrations: 5 μM
  • Incubation Time: 5 days
  • Method: For short-term expansion assays, 1 × 103 CD34+ cells are plated in triplicates in 96-well plates containing 100 μL of serum-free medium per well supplemented with human stem-cell factor (100 ng/mL), human Flt-3 Ligand (100 ng/mL), human thrombopoietin (50 ng/mL), human interleukin-3 and -6 (IL-3 and IL-6, respectively, both 20 ng/mL), and granulocyte colony-stimulating factor (20 ng/mL) along with Danusertib at the indicated concentrations. After 5 days, an additional 100 μL of cytokine and Danusertib containing medium are added. Cell numbers within each individual well are estimated on days 3, 6, and 9 or on days 3, 6, and 12 for healthy donor samples.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: Female SCID mice
  • Formulation: In DMSO
  • Dosages: 15 mg/kg
  • Administration: Intraperitoneally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 95 mg/mL (200.18 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 474.55


CAS No. 827318-97-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00872300 Terminated Multiple Myeloma Nerviano Medical Sciences October 2008 Phase 2
NCT00766324 Completed Metastatic Hormone Refractory Prostate Cancer Nerviano Medical Sciences September 2007 Phase 2
NCT00335868 Unknown status Leukemia Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) March 2007 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Danusertib (PHA-739358) | Danusertib (PHA-739358) supplier | purchase Danusertib (PHA-739358) | Danusertib (PHA-739358) cost | Danusertib (PHA-739358) manufacturer | order Danusertib (PHA-739358) | Danusertib (PHA-739358) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID